

10:30 às 13:30

Reunião dos grupos cooperativos (LACOG, GBECAM, EVA, GBOT, GTG). Apenas para convidados

13:50 às 14:00

**ABERTURA****Abertura****Carlos Sampaio e Aknar Freire de Carvalho Calabrich (BA)**

14:00 às 15:15

**MÓDULO I – GINECOLÓGICO****Moderadora: Aknar Freire de Carvalho Calabrich (BA)**

**Abstract ID: 5500 - Title: A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG oncology trial**

**Palestrante: Daniela de Freitas (SP)**

**Abstract ID: 5505 - Title: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer. A randomized controlled chemotherapy-free study—NSGO-AVANOVA2/ENGOT-OV24.**

**Palestrante: Angelica Nogueira Rodrigues (MG)**

**Abstract ID: 5506 - Title: Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial**

**Palestrante: Aknar Freire de Carvalho Calabrich (BA)**

**Abstract ID: 5508 - Title: EWOC-1: A randomized trial to evaluate the feasibility of three different first-line chemotherapy regimens for vulnerable elderly women with ovarian cancer (OC): A GCIG-ENGOT-GINECO study**

**Palestrante: Maria Del Pilar Estevez Diz (SP)****Discussão****Practice Changing****Palestrante: Angelica Nogueira Rodrigues (MG)**

15:20 às 16:30

**MÓDULO II – MELANOMA****Moderador: Sérgio Jobim de Azevedo (RS)**

**Abstract ID: 9500 - Title: Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs)**

**Palestrante: Robson Ferrigno (SP)**

**Abstract ID: 9501 - Title: Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).**

**Palestrante: Andréia Cristina de Melo (RJ)**

**Abstract ID: 9503 - Title: Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).**

**Palestrante: Sérgio Jobim de Azevedo (RS)**

**Abstract ID: 9507 - Title: Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600-mutant unresectable or metastatic melanoma.**

**Palestrante: Rodrigo Antonio Vieira Guedes (BA)****Discussão****Practice Changing****Palestrante: Andréia Cristina de Melo (RJ)**

16:30 às 17:00

**COFFEE BREAK**

17:00 as 17:15 PROJETO CURA - Entrega do Prêmio Renata Thormann Procianoy

17:15 às 19:00 MÓDULO III – PULMÃO

**Moderador:** Artur Katz (SP)

**Abstract ID:** 8502 - **Title:** Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC)

**Palestrante:** Samira da Silva Mascarenhas (BA)

**Abstract ID:** 8503 - **Title:** Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)

**Palestrante:** Clarissa Serodio da Rocha Baldotto (RJ)

**Abstract ID:** 8504 - **Title:** Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study

**Palestrante:** William Nassib William Júnior (SP)

**Abstract ID:** 8506 - **Title:** Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial

**Palestrante:** Vladimir Cláudio Cordeiro de Lima (SP)

**Abstract ID:** 9000 - **Title:** RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC)

**Palestrante:** Carolina Kawamura Haddad (SP)

**Abstract ID:** 9001 - **Title:** Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C)

**Palestrante:** Artur Katz (SP)

**Abstract ID:** 9002 - **Title:** ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC

**Palestrante:** Ana Caroline Zimmer Gelatti (RS)

**Discussão**

**Practice Changing**

**Palestrante:** William Nassib William Júnior (SP)

08:00 às 09:30

## MÓDULO IV – GENITOURINÁRIO

**Moderador:** Fernando Cotait Maluf (SP)**Abstract ID:** 4504 - **Title:** Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182**Palestrante:** Andrey Soares (SP)**Abstract ID:** 4503 - **Title:** CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma**Palestrante:** Augusto Mota (BA)**Abstract ID:** 4500 - **Title:** Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study**Palestrante:** Igor A Protzner Morbeck (DF)**Abstract ID:** 5006 - **Title:** First results from TITAN: A phase III double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).**Palestrante:** Diogo Assed Bastos (SP)**Abstract ID:** 5008 - **Title:** Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)**Palestrante:** Daniel Herchenhorn (RJ)**Abstract ID:** LBA2 - **Title:** Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international co cooperative group trial**Palestrante:** Fernando Cotait Maluf (SP)**Discussão****Practice Changing****Palestrante:** Diogo Assed Bastos (SP)

09:30 às 10:15

## SIMPÓSIO SATÉLITE ARAZENECA

**Manutenção de Lynparza em Pacientes com Câncer de Pâncreas e mutação de BRCA – POLO Trial****Palestrante:** Diogo Bugano Diniz Gomes

10:15 às 10:30

## COFFEE BREAK

10:30 às 12:10

## MÓDULO V – GASTROINTESTINAL

**Moderador:** Gustavo dos Santos Fernandes (DF)

**Abstract ID:** 3501 - Title: Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colorectal cancer (CC)

**Palestrante:** Fernanda Cunha Capareli (SP)

**Abstract ID:** 3504 - Title: FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer

**Palestrante:** Gabriel Prolla (RS)

**Abstract LBA4007:** Title: Pembrolizumab with or without chemotherapy versus chemotherapy in advanced G/GEJ adenocarcinoma: the phase 3, KEYNOTE-062 study

**Palestrante:** Túlio Pfiffer (SP)

**Abstract ID:** LBA4 - Title: Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial

**Palestrante:** Rui Fernando Weschenfelder (RS)

**Abstract ID:** 4000 - Title: AFACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma

**Palestrante:** Jorge Sabbaga (SP)

**Abstract ID:** 4003 - Title: ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

**Palestrante:** Rachel Riechelmann (SP)

Discussão

Practice Changing

**Palestrante:** Anelisa K. Coutinho (BA)

12:10 às 13:00

## SIMPÓSIO SATÉLITE NOVARTIS

Reimagine Oncology

**Chairman:** Fernando Cotait Maluf (SP)

**Speakers:** Rodrigo Munhoz (SP)

Carlos Barrios (RS)

Rui Fernando Weschenfelder (RS)

André Sasse (SP)

13:00 às 14:00

## MÓDULO VI - CABEÇA E PESCOÇO

**Moderadora:** Aline Lauda Freitas Chaves (MG)

**Abstract ID:** 6000 - Title: Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

**Palestrante:** Aline Lauda Freitas Chaves (MG)

**Abstract ID:** 6002 - Title: TPEXtreme randomized trial: TPEX versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)

**Palestrante:** Pedro Rafael Martins de Marchi (SP)



Abstract ID: 6003 - Title: Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial

Palestrante: Gilberto de Castro Junior (SP)

Discussão

Practice Changing

Palestrante: Gilberto de Castro Junior (SP)

14:00 às 14:45

SIMPÓSIO SATÉLITE LIBBS

14:45 às 16:30

MÓDULO VII – MAMA

Moderador: Rafael Kaliks (SP)

Abstract ID: 503 - Title: Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx

Palestrante: Andréa Gadêlha Guimarães (SP)

Abstract ID: 504 - Title: Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM)

Palestrante: Gilberto Amorim (RJ)

Abstract ID: 1000 - Title: SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)

Palestrante: José Bines (RJ)

Abstract ID: 1002 - Title: Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with = 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial

Palestrante: Marcelo Rocha de Sousa Cruz (SP)

Abstract ID: 1003 - Title: IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)

Palestrante: Tomás Reinert (RS)

Abstract ID: LBA1008 - Title: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results

Palestrante: Gustavo Werutsky (RS)

Discussão

Practice Changing

Palestrante: Max Mano (SP)

16:30 às 17:15

SIMPÓSIO SATÉLITE ROCHE

Impacto na prática clínica da imunoterapia em TNBC e Teste diagnóstico PD-L1 em TNBC

Palestrantes: Carlos Barrios e Fernando Soares

17:15

ENCERRAMENTO

Palestrante: Gustavo Werutsky (RS)